Clinical Trial Update: Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the effect of denosumab on inflammatory osteolytic lesion activity in the context of total hip arthroplasty is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Total Hip Arthroplasty-related Inflammatory Osteolytic Lesions

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust | Conditions: Revision Surgery of Total Hip Arthroplasty | Phase 2 | Status: COMPLETED